[89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study (2024)

Adams, H., van de Garde, E. M., van Moorsel, C. H., Vugts, D. J., van Dongen, G. A., Grutters, J. C., & Keijsers, R. G. (2019). [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study. American Journal of Nuclear Medicine and Molecular Imaging, 9(6), 296-308. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971479/

Adams, Human ; van de Garde, Ewoudt Mw ; van Moorsel, Coline Hm et al. / [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis : a feasibility study. In: American Journal of Nuclear Medicine and Molecular Imaging. 2019 ; Vol. 9, No. 6. pp. 296-308.

@article{b3bd5aafec7d4f1095ed8be3d1b496e2,

title = "[89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study",

abstract = "Recent studies on immune-mediated inflammatory lung diseases show encouraging treatment results with rituximab, a monoclonal antibody (mAb) against CD20-expressing B lymphocytes. The present pilot study aimed to explore the possibility to image CD20-expression in the lungs as future early predictor of treatment response. We describe a series of 10 patients with therapy refractory interstitial pneumonitis who were treated with rituximab (1000 mg at day 0 and day 14) and underwent PET/CT after the administration of [89Zr]Zr-N-suc-DFO-rituximab abbreviated as [89Zr]Zr-rituximab. [89Zr]-rituximab PET/CT of the chest was performed on day 3 and 6. [89Zr]Zr-rituximab PET/CT showed visual and quantifiable increased pulmonary activity in four patients. Other patients demonstrated no increased activity in the lungs. One patient developed a severe allergic reaction during infusion of the first 10% unlabeled rituximab after which rituximab infusion was ceased. Subsequent administration of [89Zr]Zr-rituximab, however, did not result in any adverse reaction. This patient demonstrated the highest uptake of [89Zr]Zr-rituximab in mediastinal lymph nodes and lung parenchyma compared to the other 9 patients who did receive the full dose rituximab before [89Zr]Zr-rituximab. This pilot study demonstrates that [89Zr]Zr-rituximab PET/CT imaging in patients with therapy refractory interstitial pneumonitis is feasible and shows lung-specific uptake in some patients. Further research with larger sample size should establish if the [89Zr]Zr-rituximab uptake correlates with treatment response to rituximab. The higher uptake in the absence of a full 1000 mg rituximab preload may suggest that future studies should consider [89Zr]Zr-rituximab imaging at low mAb dose before treatment with rituximab.",

keywords = "Rituximab, zirconium, [89Zr]Zr-rituximab PET/CT, interstitial pneumonitis, immuno-PET, pulmonary activity",

author = "Human Adams and {van de Garde}, {Ewoudt Mw} and {van Moorsel}, {Coline Hm} and Vugts, {Danielle J} and {van Dongen}, {Guus Ams} and Grutters, {Jan C} and Keijsers, {Ruth G}",

note = "AJNMMI Copyright {\textcopyright} 2019.",

year = "2019",

month = dec,

day = "15",

language = "English",

volume = "9",

pages = "296--308",

journal = "American Journal of Nuclear Medicine and Molecular Imaging",

issn = "2160-8407",

publisher = "e-Century Publishing Corporation",

number = "6",

}

Adams, H, van de Garde, EM, van Moorsel, CH, Vugts, DJ, van Dongen, GA, Grutters, JC & Keijsers, RG 2019, '[89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study', American Journal of Nuclear Medicine and Molecular Imaging, vol. 9, no. 6, pp. 296-308. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971479/>

[89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study. / Adams, Human; van de Garde, Ewoudt Mw; van Moorsel, Coline Hm et al.
In: American Journal of Nuclear Medicine and Molecular Imaging, Vol. 9, No. 6, 15.12.2019, p. 296-308.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis

T2 - a feasibility study

AU - Adams, Human

AU - van de Garde, Ewoudt Mw

AU - van Moorsel, Coline Hm

AU - Vugts, Danielle J

AU - van Dongen, Guus Ams

AU - Grutters, Jan C

AU - Keijsers, Ruth G

N1 - AJNMMI Copyright © 2019.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Recent studies on immune-mediated inflammatory lung diseases show encouraging treatment results with rituximab, a monoclonal antibody (mAb) against CD20-expressing B lymphocytes. The present pilot study aimed to explore the possibility to image CD20-expression in the lungs as future early predictor of treatment response. We describe a series of 10 patients with therapy refractory interstitial pneumonitis who were treated with rituximab (1000 mg at day 0 and day 14) and underwent PET/CT after the administration of [89Zr]Zr-N-suc-DFO-rituximab abbreviated as [89Zr]Zr-rituximab. [89Zr]-rituximab PET/CT of the chest was performed on day 3 and 6. [89Zr]Zr-rituximab PET/CT showed visual and quantifiable increased pulmonary activity in four patients. Other patients demonstrated no increased activity in the lungs. One patient developed a severe allergic reaction during infusion of the first 10% unlabeled rituximab after which rituximab infusion was ceased. Subsequent administration of [89Zr]Zr-rituximab, however, did not result in any adverse reaction. This patient demonstrated the highest uptake of [89Zr]Zr-rituximab in mediastinal lymph nodes and lung parenchyma compared to the other 9 patients who did receive the full dose rituximab before [89Zr]Zr-rituximab. This pilot study demonstrates that [89Zr]Zr-rituximab PET/CT imaging in patients with therapy refractory interstitial pneumonitis is feasible and shows lung-specific uptake in some patients. Further research with larger sample size should establish if the [89Zr]Zr-rituximab uptake correlates with treatment response to rituximab. The higher uptake in the absence of a full 1000 mg rituximab preload may suggest that future studies should consider [89Zr]Zr-rituximab imaging at low mAb dose before treatment with rituximab.

AB - Recent studies on immune-mediated inflammatory lung diseases show encouraging treatment results with rituximab, a monoclonal antibody (mAb) against CD20-expressing B lymphocytes. The present pilot study aimed to explore the possibility to image CD20-expression in the lungs as future early predictor of treatment response. We describe a series of 10 patients with therapy refractory interstitial pneumonitis who were treated with rituximab (1000 mg at day 0 and day 14) and underwent PET/CT after the administration of [89Zr]Zr-N-suc-DFO-rituximab abbreviated as [89Zr]Zr-rituximab. [89Zr]-rituximab PET/CT of the chest was performed on day 3 and 6. [89Zr]Zr-rituximab PET/CT showed visual and quantifiable increased pulmonary activity in four patients. Other patients demonstrated no increased activity in the lungs. One patient developed a severe allergic reaction during infusion of the first 10% unlabeled rituximab after which rituximab infusion was ceased. Subsequent administration of [89Zr]Zr-rituximab, however, did not result in any adverse reaction. This patient demonstrated the highest uptake of [89Zr]Zr-rituximab in mediastinal lymph nodes and lung parenchyma compared to the other 9 patients who did receive the full dose rituximab before [89Zr]Zr-rituximab. This pilot study demonstrates that [89Zr]Zr-rituximab PET/CT imaging in patients with therapy refractory interstitial pneumonitis is feasible and shows lung-specific uptake in some patients. Further research with larger sample size should establish if the [89Zr]Zr-rituximab uptake correlates with treatment response to rituximab. The higher uptake in the absence of a full 1000 mg rituximab preload may suggest that future studies should consider [89Zr]Zr-rituximab imaging at low mAb dose before treatment with rituximab.

KW - Rituximab

KW - zirconium

KW - [89Zr]Zr-rituximab PET/CT

KW - interstitial pneumonitis

KW - immuno-PET

KW - pulmonary activity

M3 - Article

C2 - 31976159

SN - 2160-8407

VL - 9

SP - 296

EP - 308

JO - American Journal of Nuclear Medicine and Molecular Imaging

JF - American Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -

Adams H, van de Garde EM, van Moorsel CH, Vugts DJ, van Dongen GA, Grutters JC et al. [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study. American Journal of Nuclear Medicine and Molecular Imaging. 2019 Dec 15;9(6):296-308.